Astec LifeSciences launches Adi Godrej Center for Chemical Research and Development
Mumbai, April 12th, 2023: Astec LifeSciences Limited, a subsidiary of Godrej Agrovet Limited (GAVL), today launched its new advanced research and development (R&D) Center in Rabale, Maharashtra. Named the ‘Adi Godrej Center for Chemical Research and Development’, the facility will focus on leading-edge innovation and developing sustainable & safe solutions for people and the environment and providing services to innovator companies in contract development & manufacturing space (CDMO).
Focused on new product generation, process optimization & scale-up along with product life-cycle management, the R&D Center will catalyze Godrej Group’s ambition to be an application-agnostic partner of choice for innovator companies in the rapidly growing chemical industry.
The state-of-the-art R&D Center is equipped with a synthesis lab for product synthesis and a formulation lab to develop new formulations in crop protection space. Supported with advanced analytical instruments to drive R&D, the center also houses sophisticated process safety infrastructure to undertake safe and sustainable chemical reactions.
Given its capabilities, the new R&D Center will enable the company to develop a newer range of sustainable products at a faster pace and at a greater scale, thereby adding value to its customers’ businesses, without compromising on ethics, safety and care for the environment.
Commenting on the launch, Nadir Godrej, Chairman, GAVL said, “The launch of the R&D Center in Rabale is a significant milestone for Astec LifeSciences in our quest to tap immense potential in the chemical industry. Designed to be a hub of cutting-edge research and development, equipped with state-of-the-art facilities and staffed by some of the brightest minds in the field, at Godrej, we continue to foster curiosity and culture of innovation. A testament to our commitment to offering advanced solutions with a focus on green chemistry and sustainability, I am happy that our R&D capability and world-class infrastructure will add value for our stakeholders, employees and customers.”
Emphasizing on the need to invest in setting up a new R&D Center, Balram Singh Yadav, Managing Director, GAVL said, “India is an emerging frontier in the chemicals space. However, harnessing its full potential will require an enabling eco-system and that’s where this R&D Center comes in. The potential in this sector, not just domestically but also globally is huge, and we are confident that with our R&D capabilities and the backing of the trusted Godrej brand will make us future ready and position us at the very cutting edge of the sector.”
Highlighting the potential benefits for its clients and company, Anurag Roy, Chief Executive Offer, Astec LifeSciences Ltd. said, “The CDMO market for chemicals in India is expected grow at a CAGR of 12% as against global rate of 10%. This underlines the incredible potential in this sector, and it is herein our new facility will enable us to expand our offerings specifically in CDMO space. Equipping us to tap on new opportunities, it will also make us a partner of choice through our improved ability of providing end-to-end solutions to our customers – from the R&D stage to development to the commercialization of products. Slashing the time-to-market for innovative solutions, we are confident that by improving product development, providing access to advanced equipment and facilities, fostering collaboration, and driving innovation, the new R&D Center will cement us at the right place in the sector at the right time.”
India is becoming the preferred hub for the chemical sector due to availability of skilled technical manpower, raw materials, and a strong IP regime. Astec LifeSciences Ltd aims to make a difference with its strong research and infrastructure capability, smooth and faster scale-up capability and world-class HSEQ standards. The company is investing heavily in building up its expertise and has hired over a 100 chemists and engineers with a plans to double the same during FY2023-24.